- Home
- USIO vs ABVC Comparison
USIO vs ABVC Comparison
Compare USIO & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USIO
- ABVC
- Stock Information
- Founded
- USIO 1998
- ABVC 2015
- Country
- USIO United States
- ABVC United States
- Employees
- USIO N/A
- ABVC N/A
- Industry
- USIO Investment Bankers/Brokers/Service
- ABVC Biotechnology: Pharmaceutical Preparations
- Sector
- USIO Finance
- ABVC Health Care
- Exchange
- USIO Nasdaq
- ABVC Nasdaq
- Market Cap
- USIO 50.2M
- ABVC 52.1M
- IPO Year
- USIO N/A
- ABVC N/A
- Fundamental
- Price
- USIO $1.46
- ABVC $2.72
- Analyst Decision
- USIO Strong Buy
- ABVC
- Analyst Count
- USIO 1
- ABVC 0
- Target Price
- USIO $4.00
- ABVC N/A
- AVG Volume (30 Days)
- USIO 88.1K
- ABVC 117.4K
- Earning Date
- USIO 11-05-2025
- ABVC 08-13-2025
- Dividend Yield
- USIO N/A
- ABVC N/A
- EPS Growth
- USIO N/A
- ABVC N/A
- EPS
- USIO 0.11
- ABVC N/A
- Revenue
- USIO $83,851,606.00
- ABVC $391,242.00
- Revenue This Year
- USIO $8.66
- ABVC $735.18
- Revenue Next Year
- USIO $13.32
- ABVC N/A
- P/E Ratio
- USIO $13.42
- ABVC N/A
- Revenue Growth
- USIO 2.05
- ABVC 186.84
- 52 Week Low
- USIO $1.24
- ABVC $0.40
- 52 Week High
- USIO $2.92
- ABVC $5.48
- Technical
- Relative Strength Index (RSI)
- USIO 44.97
- ABVC 45.17
- Support Level
- USIO $1.43
- ABVC $2.51
- Resistance Level
- USIO $1.55
- ABVC $3.14
- Average True Range (ATR)
- USIO 0.07
- ABVC 0.21
- MACD
- USIO -0.00
- ABVC -0.04
- Stochastic Oscillator
- USIO 44.44
- ABVC 24.85
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.